Acadia Pharmaceuticals (ACAD) Work In Process (2018 - 2026)

Acadia Pharmaceuticals' Work In Process history runs 9 years deep, the most recent figure standing at $80.7 million for Q1 2026.

• In Q1 2026, Work In Process rose 0.87% year-over-year to $80.7 million; the TTM figure through Mar 2026 stood at $80.7 million (up 0.87% YoY), while the FY2025 annual figure was $76.7 million, up 9.98% from the prior year.
• Work In Process was $80.7 million for Q1 2026 at Acadia Pharmaceuticals, up from $76.7 million in the prior quarter.
• In the past five years, Work In Process ranged from a high of $84.4 million in Q2 2025 to a low of $4.6 million in Q3 2023.
• Historically, Work In Process has averaged $32.8 million across 5 years, with a median of $6.2 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Work In Process decreased 27.24% in 2022, then soared 1406.94% in 2024.
• A 5-year view of Work In Process shows it stood at $4.9 million in 2022, then dropped by 6.01% to $4.6 million in 2023, then jumped by 1406.94% to $69.7 million in 2024, then advanced by 9.98% to $76.7 million in 2025, then increased by 5.23% to $80.7 million in 2026.
• The last three Work In Process figures came in at $80.7 million (Q1 2026), $76.7 million (Q4 2025), and $76.9 million (Q3 2025), per Business Quant data.